<DOC>
	<DOCNO>NCT00337779</DOCNO>
	<brief_summary>Teva develop 40 mg/ml GA Injection , administer daily skin , treatment R-R MS . The study drug high dose formulation CopaxoneÂ® ( 20 mg/ml GA ) , market medication , approve treatment R-R MS. GA immunomodulating drug anti inflammatory neuroprotective property . The study treatment duration 12 month .</brief_summary>
	<brief_title>Clinical Trial Comparing Treatment Relapsing-Remitting Multiple Sclerosis ( RR-MS ) With Two Doses Glatiramer Acetate ( GA ) .</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis , Relapsing-Remitting</mesh_term>
	<mesh_term>Glatiramer Acetate</mesh_term>
	<criteria>1 . Diagnosis confirm documented MS define Revised McDonald criterion . 2 . Subjects must relapsingremitting ( RR ) type . 3 . Subject experience prior screen least one document relapse 12 month least 2 documented relapse 24 month one document relapse 12 24 month least 1 document T1Gd enhance lesion MRI perform 12 month prior screen . 4 . Disease duration least 6 month . 5 . Ambulatory convert Kurtzke EDSS score 0 5 . 6 . Relapse free stable neurological condition least 30 day prior screen . 7 . Age 1855 ( inclusive ) 1 . Previous use Copaxone ( glatiramer acetate ) 2 . Treatment corticosteroid within 30 day prior screen screen baseline . 3 . Chronic corticosteroid treatment 30 consecutive day . 4 . Subject clinically significant unstable medical condition . 5 . Subjects participate clinical trial ( within 12 week prior screen thereafter ) . 6 . Known history sensitivity Gadolinium inability successfully undergo MRI scanning .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>October 2011</verification_date>
</DOC>